FORMULA FOR OUR SUCCESS
Kineta's area of specialization is translational research. To some this period is known as, "the valley of death." Our team regards it as a niche of opportunity. We have a refined process for selecting superb preclinical drug programs and rapidly advancing them into phase 1 of the clinical pipeline.

Our scientists are working on treatments for infectious, inflammatory and autoimmune diseases developing drugs that work in concert with the immune system. Our novel programs have broad pharmaceutical applications and will advance into the clinical pipeline amid the extraordinary wave of patent expiry in the pharmaceutical industry. This trend has generated tremendous market demand for new and better products in early clinical development.

Kineta is a privately held corporation that seeks investors and financial partners who share our vision of helping humanity through our robust scientific programs, a sustainable business enterprise and a fresh approach to biotechnology. We encourage health-focused research foundations and investment funds, private investors and trusts to learn more about Kineta, Inc. For additional information contact Ken North, Senior Vice President, Finance, knorth@kinetabio.com, 206-378-0400.